Celldex Therapeutics, Inc.
Income Statement
| Line Item | Jun 2026 | Mar 2026 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $22.0K | $15.0K | $730.0K | $695.0K | $1.2M | $3.2M | $2.5M | $156.0K |
| Cost of Revenue | — | — | — | — | — | — | — | — |
| Gross Profit | — | — | — | — | — | — | — | — |
| Gross Margin | — | — | — | — | — | — | — | — |
| Operating Expenses | ||||||||
| Research & Development | $67.5M | $73.0M | $54.2M | $52.6M | $46.9M | $45.3M | $39.7M | $31.7M |
| SG&A Expense | $13.1M | $11.4M | $10.4M | $10.8M | $10.3M | $10.1M | $9.1M | $9.1M |
| Operating Income | $-80.6M | $-84.4M | $-63.9M | $-62.7M | $-56.0M | $-52.1M | $-46.3M | $-40.6M |
| Operating Margin | -366,468.2% | -562,900.0% | -8,747.5% | -9,027.2% | -4,768.3% | -1,633.5% | -1,854.2% | -26,030.8% |
| Interest Expense | — | — | — | — | — | — | — | — |
| Pretax Income | — | — | — | — | — | — | — | — |
| Income Tax Expense | — | — | — | — | — | — | — | — |
| Net Income | $-73.5M | $-78.7M | $-56.6M | $-53.8M | $-47.1M | $-42.1M | $-35.8M | $-32.8M |
| Net Margin | -334,104.5% | -524,566.7% | -7,753.4% | -7,740.4% | -4,007.8% | -1,320.0% | -1,434.8% | -21,030.8% |
| EPS (Basic) | $-0.94 | $-1.18 | $-0.85 | $-0.81 | $-0.71 | $-0.64 | $-0.54 | $-0.56 |
| EPS (Diluted) | $-0.94 | $-1.18 | $-0.85 | $-0.81 | $-0.71 | $-0.64 | $-0.54 | $-0.56 |
| Shares Outstanding (Basic) | 77.8M | 66.6M | 66.4M | 66.4M | 64.4M | 66.3K | 66.0K | 58.9K |
| Shares Outstanding (Diluted) | 77.8M | 66.6M | 66.4M | 66.4M | 64.4M | 66.3K | 66.0K | 58.9K |
| Dividends Per Share | — | — | — | — | — | — | — | — |